Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2021
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:clinicalTrialPhase |
Phase III
|
| gptkbp:developedBy |
gptkb:Mirati_Therapeutics
gptkb:Amgen |
| gptkbp:example |
gptkb:adagrasib
gptkb:sotorasib |
| gptkbp:hasApprovedDrug |
gptkb:sotorasib
|
| https://www.w3.org/2000/01/rdf-schema#label |
KRAS G12C inhibitors
|
| gptkbp:mechanismOfAction |
covalent binding to KRAS G12C mutant
|
| gptkbp:resistantTo |
activation of alternative pathways
secondary KRAS mutations |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
diarrhea fatigue elevated liver enzymes |
| gptkbp:target |
gptkb:KRAS_G12C_mutant_protein
|
| gptkbp:usedFor |
gptkb:non-small_cell_lung_cancer
colorectal cancer |
| gptkbp:bfsParent |
gptkb:Ras_protein_family
gptkb:Rat_sarcoma_protein |
| gptkbp:bfsLayer |
7
|